`Petition for Inter Partes Review
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`
`
`
`
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`
`
`
`
`FRESENIUS KABI USA, LLC,
`Petitioner
`
`v.
`
`CEPHALON, INC.,
`Patent Owner
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Case IPR2016-00111
`Patent No. 8,895,756
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`PETITIONER’S OBJECTIONS TO EVIDENCE
`
`
`
`Mail Stop: Patent Board
`Patent Trial and Appeal Board
`United States Patent and Trademark Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`
`
`
`
`
`
`
`
`IPR2016-00111
`Petition for Inter Partes Review
`
`
`Pursuant to 37 C.F.R. § 42.63(b)(1), Petitioner Fresenius Kabi USA, LLC
`
`(“Fresenius”) asserts the following objections to evidence submitted by Patent
`
`Owner Cephalon, Inc. (“Cephalon”) in its Preliminary Patent Owner Response
`
`(“Prel. Resp.”). Fresenius reserves the right to file a motion to exclude the
`
`evidence to which these objections are directed.
`
`Fresenius objects to Exhibits 2002, 2004, and 2005 under FRE 801-802 and
`
`901. These exhibits appear to be printouts from a website, Drugs.com. Cephalon
`
`is proffering these exhibits for the truth of the matter asserted in support of certain
`
`secondary considerations arguments (Prel. Resp. at 11), but has not shown that any
`
`applicable exception to the hearsay rule applies. Cephalon has also not provided
`
`any evidence demonstrating the authenticity of the website printouts.
`
`Fresenius objects to Exhibits 2006-2010 and 2011-2015 under FRE 401-403.
`
`Cephalon offered
`
`these exhibits
`
`in connection with purported secondary
`
`considerations arguments. Prel. Resp. at 11. These exhibits should be excluded
`
`because Cephalon has failed to establish a nexus between the claimed invention
`
`and the alleged secondary consideration.
`
`In particular, Cephalon has not provided any evidence or analysis showing
`
`that the alleged secondary consideration is attributable to the claimed invention as
`
`opposed to elements in the prior art, such as the bendamustine hydrochloride active
`
`pharmaceutical ingredient. See In re Huai-Hung Kao, 639 F.3d 1057, 1068 (Fed.
`
`
`
`1
`
`
`
`IPR2016-00111
`Petition for Inter Partes Review
`
`Cir. 2011) (“Where the offered secondary consideration actually results from
`
`something other than what is both claimed and novel in the claim, there is no nexus
`
`to the merits of the claimed invention.”). Cephalon’s failure to establish such a
`
`nexus renders its alleged secondary consideration evidence inadmissible. See, e.g.,
`
`Merck & Co. v. Teva Pharms. USA, Inc., 395 F.3d 1364, 1376-77 (Fed. Cir. 2005);
`
`Ormco Corp. v. Align Tech., Inc., 463 F.3d 1299, 1312 (Fed. Cir. 2006) (absent
`
`nexus, “[e]vidence of commercial success, or other secondary considerations” is
`
`“irrelevant”).
`
`
`
`
`
`
`
`
`
`2
`
`
`
`IPR2016-00111
`Petition for Inter Partes Review
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Respectfully submitted,
`
`WILEY REIN LLP
`
`
`
`
`By:
`
`
`
`/Lawrence Sung, #38,330/
`
`Lawrence Sung, Reg. No. 38,330
`
`
`
`
`
`
`
`3
`
`
`
`
`
`
`
`
`
`
`
`
`
`IPR2016-00111
`Petition for Inter Partes Review
`
`
`CERTIFICATE OF SERVICE ON PATENT OWNER
`UNDER 37 C.F.R. § 42.105(A)
`
`
`
`The undersigned hereby certifies that a copy of the foregoing document was
`
`served via electronic mail on May 18, 2016 to the following counsel of record for
`
`the Petitioner:
`
`
`Soumitra Deka
`Aaron Stiefel
`KAYE SCHOLER LLP
`Soumitra.deka@kayescholer.com
`Aaron.stiefel@kayescholer.com
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`/Lawrence Sung, #38,330/
`
` Lawrence Sung, Reg. No. 38,330